Daniel Bride
YOU?
Author Swipe
View article: Effectiveness of 2024–2025 COVID-19 Vaccines in Children in the United States — VISION, August 29, 2024–September 2, 2025
Effectiveness of 2024–2025 COVID-19 Vaccines in Children in the United States — VISION, August 29, 2024–September 2, 2025 Open
During September 2023-August 2024, approximately 38,000 COVID-19-associated hospitalizations occurred among children and adolescents aged <18 years in the United States, a rate of approximately 53 per 100,000 children, ranging from 600 per…
Risk of venous thromboembolism associated with short-term exposure to fine particulate matter (PM2.5) and ozone air pollution Open
We found little evidence that short-term air pollution exposure increases VTE risk. However, short-term PM2.5 and short-term ozone exposure may variably confer risk for VTE when stratified by wildfire and inversion seasons.
View article: Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysis
Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysis Open
This work was supported by the Centers for Disease Control and Prevention (contracts 75D30121D12779 to Westat and 75D30123C18039 to Kaiser Foundation Hospitals).
View article: Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults
Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults Open
Importance SARS-CoV-2 continues to evolve, population immunity changes, and COVID-19 vaccine formulas have been updated, necessitating ongoing COVID-19 vaccine effectiveness (VE) monitoring. Objectives To evaluate the VE of 2023-2024 COVID…
View article: Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness — Four Vaccine Effectiveness Networks, United States, October 2024–February 2025
Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness — Four Vaccine Effectiveness Networks, United States, October 2024–February 2025 Open
Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hos…
View article: Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025
Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025 Open
COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2…
View article: P-51. Influenza Vaccine Effectiveness in Ambulatory Care Settings among Pregnant Persons in the 2023-2024 Influenza Season
P-51. Influenza Vaccine Effectiveness in Ambulatory Care Settings among Pregnant Persons in the 2023-2024 Influenza Season Open
Background Despite increased risk of influenza-associated complications in pregnant people, influenza vaccination coverage has decreased in recent seasons as vaccine confidence has declined. The purpose of this study was to evaluate influe…
View article: Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023–2024 Season, United States
Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023–2024 Season, United States Open
Background The 2023–2024 influenza season had predominant influenza A(H1N1)pdm09 virus activity, but A(H3N2) and B viruses cocirculated. Seasonal influenza vaccine strains were well-matched to these viruses. Methods Using healthcare encoun…
Lack of Association Between Donor‐Derived Cell‐Free DNA and Cardiac Allograft Vasculopathy Open
Cardiac allograft vasculopathy (CAV) is a leading cause of death after heart transplantation (HT). We evaluated donor‐derived cell‐free DNA (dd‐cfDNA) as a noninvasive biomarker of CAV development after HT. The INSPIRE registry at the Inte…
Associations of air pollution with acute coronary syndromes based on A/B/AB versus O blood types: case-crossover study Open
Short-term exposure to air pollutants may contribute to an increased risk of acute coronary syndrome (ACS). This study assessed the role of short-term exposure to fine particulate matter (PM 2.5 ) as well as fine and coarse PM (PM 10 ) air…
View article: Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024 Open
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. As with past COVID-…
View article: Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States
Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States Open
In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months. Using data from four vaccine effectiveness (VE) networks during the 2023-24 influenza season, interim influenza VE was estimated among patien…
View article: Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024 Open
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few estima…
Associations of Air Pollution with Acute Coronary Syndromes Based on A/B/AB vs. O Blood Types – Case-crossover Study Open
Aims: Short-term exposure to air pollutants may contribute to an increased risk of acute coronary syndrome (ACS). This study assessed the role of short-term exposure to fine particulate matter (PM 2.5 ) as well as fine and coarse PM (PM 10…
View article: OC 72.3 Risk of Pulmonary Embolism and Deep Vein Thrombosis Associated with Short-Term Air Pollution
OC 72.3 Risk of Pulmonary Embolism and Deep Vein Thrombosis Associated with Short-Term Air Pollution Open
Results: 625 patients (231 women, median age 66 years) were included for a median observation time of 870 days (IQR, 391-1234 days).VTE occurred in 24 patients (3.8%), including 20 deep vein thrombosis and 7 pulmonary emboli, and VAT occur…
View article: A highly predictive cardiac positron emission tomography (PET) risk score for 90-day and one-year major adverse cardiac events and revascularization
A highly predictive cardiac positron emission tomography (PET) risk score for 90-day and one-year major adverse cardiac events and revascularization Open
The derived PET/CT 90-day and one-year MACE-Revasc risk scores were highly predictive and outperformed ischemic burden and cardiologist assessment. These scores are easy to calculate, lending to straightforward clinical implementation and …
Behavioral Nudges as Patient Decision Support for Medication Adherence: The ENCOURAGE Randomized Controlled Trial Open
Medication adherence is generally low and challenging to address because patient actions control healthcare delivery outside of medical environments. Behavioral nudging changes clinician behavior, but nudging patient decision-making requir…